Wednesday, August 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 3, 2025

Genetic Testing Market Research Report 2025-2030: Advances in Genomics, Aging Populations, Pharmacogenomics, Oncology Liquid Biopsies, Fertility Testing, and Rising DTC Adoption Driving Growth

View original at globenewswire.com
Genetic Testing Market Research Report 2025-2030: Advances in Genomics, Aging Populations, Pharmacogenomics, Oncology Liquid Biopsies, Fertility Testing, and Rising DTC Adoption Driving Growth Dublin, Nov…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The traditional genetic testing market is growing in volume and the number of tests, creating new opportunities and challenges for the industry

    80% confidence
  • The genetic testing market has unlimited growth potential and has crossed the chasm, now growing in every area

    80% confidence
  • The report covers 14 countries and 5 regions with detailed market breakouts

    80% confidence
  • Lower pricing combined with new knowledge about genetics in health and disease is driving the genetic testing industry to record growth

    80% confidence
  • Advances in genomics, aging populations, pharmacogenomics, oncology liquid biopsies, fertility testing, and rising DTC adoption are key drivers of genetic testing market growth for 2025-2030

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Query this data → isubstrate.com
Genetic Testing Market Research Report 2025-2030: Advances in Genomics, Aging Populations, Pharmacogenomics, Oncology Liquid Biopsies, Fertility Testing, and Rising DTC Adoption Driving Growth — Source | Via News | ViaNews Market